Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 232

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 232
---
 on January 22, 2024. The Board of Directors has determined that Dr. de Vries and Dr. Turton and
Ms. Merchant are independent.

The Remuneration Committee
of the Board of Directors is responsible, within agreed terms of reference, for establishing a formal and transparent procedure for developing
policy on executive remuneration and setting the remuneration packages of individual directors. This includes agreeing with the Board
of Directors on the framework for remuneration of the executive directors, the company secretary and such other members of our executive
management as it is designated to consider. It is also responsible for determining the total individual remuneration packages of each
director including, where appropriate, bonuses, incentive payments and share options. No director may be involved in any decision as to
his/her own remuneration. The Remuneration Committee ensures compliance with the QCA Code in relation to remuneration wherever possible.

The Remuneration Committee meets not less than
twice a year and otherwise as required.

Service Contracts

Except as described herein,
we do not have service contracts with any member of our Board of Directors or our senior management.

Equity Benefit Plans

The Board of Directors has
established the Biodexa Pharmaceuticals PLC Enterprise Management Incentive and Unapproved Share Option Scheme, or Plan, to allow us to
grant options to purchase Ordinary Shares (in the form of Depositary Shares) to employees and directors of the Company or any of its subsidiaries,
or Plan Participants, for the purpose of attracting, rewarding and retaining such persons. The Plan was originally adopted in December
2014 and amended on April 11, 2024 to govern the grant of tax-advantaged enterprise management incentive stock options, or EMI Options,
and unapproved stock options, or Unapproved Options, by the Company.

Administration. The
overall responsibility for the operation and administration of the Plan is vested in the Board of Directors.

Eligibility. Unapproved
Options may be granted to any person who is an employee or director of the Company or any of its subsidiaries. However, in order to be
eligible to be granted EMI Options pursuant to the Plan, a person must be an employee or director of the Company or any of its subsidiaries
whose “committed time” amounts to at least 25 hours a week or, if less, 75% of his or her “working time,” as each
of those terms are defined under the His Majesty’s Revenue and Customs rules set out in